A former executive at Standard Register Healthcare, Kevin Lilly is an experienced technology professional with many years working in the healthcare field. Until recently, Kevin Lilly worked as the senior vice president of sales at MiMedX, a company specializing in biomedical research into regenerative biologicals, such as AmnioFix, a placental tissue matrix allograft. Below are some common questions people have about placental tissue matrix therapy.
Q: What is a placental tissue matrix?
A: Derived from amniotic tissue, these products promote and support the repair of soft tissues and minimize the creation of scar tissue as well as reduce inflammation.
Q: Are placental tissue matrix therapies safe?
A: Yes. The therapies are cleared by the FDA for use in the United States and there is no evidence that placental tissue matrix products cause cancer, transmit genetic diseases, or result in tissue rejection.
Q: How does the therapy work?
A: In the most basic sense, a placental tissue matrix is introduced to your body by injection to replace injured tissue. Once injected, the placental tissue cells help regenerate the damaged and unhealthy tissue. There are several forms of this therapy available depending on the application.
Kevin Lilly 